Treatment Of Chronic Prostatitis Research Articles

A systematic review and meta-analysis of moxibustion for chronic prostatitis.

Chronic prostatitis (CP) is a common condition that affects many individuals. Previous clinical trials have explored the use of moxibustion as a potential treatment for CP. However, the evidence on the effectiveness of moxibustion for CP remains limited. Therefore, this study aimed to comprehensively assess the effects of moxibustion for CP. In order to gather relevant and up-to-date information, we conducted a systematic literature search of databases including Cochrane Library, PUBMED, EMBASE, CNKI, and Wangfang from inception until June 30, 2023. Only randomized clinical trials (RCTs) that investigated the use of moxibustion for CP were included in this study. The primary outcomes of interest were the National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) scores and the overall response rate. To evaluate the quality of the included studies, we used the Cochrane risk-of-bias tool. After analyzing the data from 8 RCTs involving a total of 664 patients, we found significant differences in NIH-CPSI scores between moxibustion and other treatment modalities. Specifically, when compared with herbal medicine, moxibustion was associated with a mean difference (MD) of -1.78 in NIH-CPSI scores (95% confidence interval [CI] [-2.78, -0.78], P < .001), and when compared with western medicine, moxibustion was associated with a MD of -5.24 in NIH-CPSI scores (95% CI [-7.80, -2.67], P < .08). In terms of the overall response rate, moxibustion was found to be superior to herbal medicine, with a MD of 2.36 (95% [19, 4.67], P = .01). Additionally, when moxibustion was combined with herbal medicine, it yielded a higher overall response rate with a MD of 4.07 (95% CI [1.54, 10.74], P = .005) compared to herbal medicine alone. Moxibustion also outperformed western medicine in terms of the overall response rate, with a MD of 4.56 (95% CI [2.24, 9.26], P < .001). Based on the findings of this study, moxibustion appears to be a potentially efficacious treatment for CP. The results suggest that moxibustion can improve NIH-CPSI scores and overall response rate in patients with CP. However, further high-quality studies are needed to validate these results and establish the long-term effects of moxibustion as a treatment for CP.

Low intensity extracorporeal shockwave therapy for chronic pelvic pain syndrome: Long-term follow-up.

Chronic prostatitis (CP) is one of the diseases that reduce the quality of life (QoL) of young men. To date, there is no consensus on the management of these patients. It is essential to continue research into the treatment of CP, despite the use of various therapies, including low-energy extracorporeal shockwave therapy (ESWT). The main objective of this study is to observe and record the clinical symptomatology of patients during a 48-week follow-up period after ESWT treatment. Between 2019 and 2021, 28 patients with type IIIB CP/chronic pelvic pain syndrome were enrolled. Patients underwent ESWT once weekly for 4 weeks (3,000 individual sessions, maximum total energy flux density 0.25 mJ/mm2, frequency 3 Hz). Participants were assessed at 0, 4, 12, 24, 36 and 48 weeks post-treatment using the visual analogue scale (VAS), National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), and International Index of Erectile Function (IIEF)-5. The mean age of patients was 47.1 ± 13.7 years (range 28-4 years). The positive effect of LI-ESWT was reflected in improvements in VAS, NIH-CPSI, and IIEF-5 scores. Regression of patients' symptoms was observed as early as 4 weeks after treatment. The greatest progress was achieved at week 24. In addition, a slight worsening was observed at week 36 and 48, with stable progress. The treatment significantly improved the QoL of the patients, with the most significant improvement in the VAS score. In conclusion, this treatment approach is safe, most effective in the first 6 months. Thereafter, the efficacy of the treatment diminishes, but is sustained over a longer period.

Review of Daozhuo Massage Therapy for Chronic Prostatitis

Daozhuo massage therapy for chronic prostatitis is an external treatment method that uses pointing, pressing, pushing, and kneading on specific acupoints to dredge meridians, regulate qi, and activate blood circulation. This therapy has a noticeable clinical therapeutic effect on chronic prostatitis, which is the core syndrome type of blood stasis. This article reviews the Traditional Chinese Medicine (TCM) pathogenesis of chronic prostatitis, the historical overview, clinical application, and operational precautions of Daozhuo massage therapy. It also includes a case study to discuss the significant role, effectiveness, and practical application of Daozhuo massage therapy in the clinical diagnosis and treatment of chronic prostatitis.

Ursolic acid alleviates chronic prostatitis via regulating NLRP3 inflammasome-mediated Caspase-1/GSDMD pyroptosis pathway.

Ursolic acid (UA) is a naturally occurring pentacyclic triterpenoid widely found in fruits and vegetables. It has been reported that UA has anti-inflammatory effects. However, its efficacy and mechanism of action in the treatment of chronic prostatitis (CP) remain unclear. This study aimed to investigate the efficacy of UA treatment in CP and further explore the underlying mechanism. CP rat and pyroptosis cell models were established in vivo and in vitro, respectively. The efficacy of UA in inhibiting CP was evaluated via haematoxylin-eosin (HE) staining and measurement of inflammatory cytokines. RNA sequencing and molecular docking were used to predict the therapeutic targets of UA in CP. The expression of pyroptosis-related proteins was examined using various techniques, including immunohistochemistry, immunofluorescence, and flow cytometry. UA significantly ameliorated pathological damage and reduced the levels of proinflammatory cytokines in the CP model rats. RNA sequencing analysis and molecular docking suggested that NLRP3, Caspase-1, and GSDMD may be key targets. We also found that UA decreased ROS levels, alleviated oxidative stress, and inhibited p-NF-κB protein expression both in vivo and in vitro. UA improved pyroptosis morphology as indicated by electron microscope and inhibited the expression of the pyroptosis-related proteins NLRP3, Caspase-1, ASC, and GSDMD, reversed the levels of IL-1β, IL-18, and lactate dehydrogenase in vivo and in vitro. UA can mitigate CP by regulating the NLRP3 inflammasome-mediated Caspase-1/GSDMD pathway. Therefore, UA may be a potential for the treatment of CP.

Clinical Study on Treatment of Chronic Prostatitis with Lingze Tablets Combined with TCM Herbal Acupoint Plasters

Objective: To study the therapeutic effect of Lingze tablets combined with traditional Chinese medicine herbalacupoint plasters on chronic prostatitis. Methods: A total of 64 patients with chronic prostatitis who were admitted to the Andrology Clinic of Shuyang County Hospital of Traditional Chinese Medicine from March 2021 to March 2023 were randomly divided into a treatment group and a control group, with 32 cases in each group. The control group took Lingze tablets orally, 4 tablets/time, 3 times/d; the treatment group took the same medication along with traditional Chinese medicine acupoint herbal plasters. The two groups of patients were treated continuously for 6 weeks, and the differences in the relevant indexes of the curative effect were observed. Results: The NIH-Chronic Prostatitis Symptom Index (NIH-CPSI) scores of the two groups significantly reduced after treatment (P &lt; 0.05), and the scores of the patients in the treatment group were lower than those in the control group (P &lt; 0.05). The treatment received in the treatment group achieved and efficacy of 96.88%, which was significantly higher than that of the group, which was 81.25% (P &lt; 0.05). The maximum flow rate (MFR), average flow rate AFR, and urine output of the patients of both groups improved significantly after treatment (P &lt; 0.05). However, the experimental group showed better improvements in these indicators (P &lt; 0.05). Conclusion: Lingze tablets combined with traditional Chinese medicine acupoint herbal plasters can significantly improve the symptoms and urodynamic function of patients with chronic prostatitis.

Application of the UPOINT classification to determine indications for antibacterial therapy of chronic inflammatory process

Background. Patients with chronic prostatitis (CP) represent the majority of urological referral. The most patients, independent of their age, visit attending urologists constantly.&#x0D; Aim. To evaluate the rate of antibiotics prescriptions based on the UPOINTS chronic prostatitis classification and the estimation of its efficacy.&#x0D; Materials and methods. In 2022–2023 there were enrolled 92 CP patients in the Pletnev City Clinical Hospital and Vishnevsky National Medical Research Center for High Medical Technologies – Central Military Clinical Hospital. The age varies from 22 to 46 year (mean 34±8). The diagnosis lifespan was – 11+16.5 mo. The NIH-CPSI score was 23±6.1 (pain 8±5.5, urination – 7±2.4, life quality 8±3.6). The prostate volume was 26±8 cc. The positive Meares-Stamey test was occurred in 38/92 (41%) cases. The positive prostate or sperm culture were found in 18/92 (20%) pts. The positive PCR-tests were obtained in 32/42 (76%) urethral samples, prostate secretes 23/42 (55%) and sperm – 20/42 (48%). Fluorochinilones were prescribed in all 92 (100%) cases, tetracycline (66 patients, 72%) and macrolides – 48 patients, 52%.&#x0D; Results. Sixty eight (74%) pts have passed the follow-up. The total NIH-CSPI score decreased to 15±5.3 (pain – 6±3.6, urination – 5±2.1, life quality 4±2). The average prostate volume was 23±4 cc, at 86% (58) cases were achieved the laboratory tests normalization. The fluorchinolones efficacy was – 29% (17 patients), tetracycline – 41% (24 patients), macrolides – 29% (17 patients).&#x0D; Conclusion. The UPOINT classification use allows optimize the CP management. PCR-tets are the most sensitive in terms of the I-type CP diagnosis. The administration of Doxycycline Express® in the I-type of CP treatment is the most effective (41%) in the comparison to the other antibiotics.

The Study of the Effectiveness of Modern Phytotherapy for Patients with Benign Prostatic Hyperplasia and Chronic Prostatitis

The objective: to analyze the effectiveness and tolerability of a dietary supplement, which includes: Saw Palmetto (Serenoa repens), pumpkin seeds (Cucurbita moschata), African tuber (Hypoxis hemerocallidea), stinging nettle root (Urtica dioica), African plum bark (Prunus africana), rye pollen extract (Secale cereale), in the treatment of patients with benign prostatic hyperplasia (BPH) and chronic prostatitis (CP) for 6 months. Materials and methods. 60 men were examined, they were divided into two groups: the main group (MG) – 28 patients who received the dietary supplement for 6 months, and the comparison group (CG) – 32 patients who used another combined herbal preparation for the treatment of BPH and CP. MG and CG patients were similar in terms of age, disease duration, and urination rate. Patients of both groups were examined using clinical, laboratory and instrumental methods before the start of treatment and after its completion in 6 months. Results. The main result of the research can be considered that the use of a dietary supplement based on Saw Palmetto (Serenoa repens), pumpkin seeds (Cucurbita moschata), African tuber (Hypoxis hemerocallidea), stinging nettle root (Urtica dioica), African plum bark (Prunus africana), extract of rye pollen (Secale cereale) gives an excellent long-term effect in 96.4% of patients with CP and BPH. As a result of the study, this dietary supplement demonstrated its effectiveness in the treatment of patients with BPH and CP for both subjective (IPSS and QOL, pain sensation) and objective indicators over a period of 6 months. During therapy the volume of residual urine in patients probably decreased and the maximum urinary flow rate increased. Conclusions. Dietary supplement, which includes Saw Palmetto (Serenoa repens), pumpkin seeds (Cucurbita moschata), African tuber (Hypoxis hemerocallidea), nettle root (Urtica dioica), African plum bark (Prunus africana), rye pollen extract (Secale cereale), is well tolerated by patients, has high therapeutic efficiency, does not cause side effects, does not disturb the sexual function of patients with BPH and CP, which allows to prescribe it for a long time.

Amelioration of chronic prostatitis by fractions of Mongolian medicine Hosta plantaginea flowers via inhibition of NF-κB, MAPKs, JAK-STAT, and PI3K-Akt signaling pathways in rats.

Hosta plantaginea (Lam.) Aschers flower is an important Mongolian medicine beneficial in the treatment of chronic prostatitis (CP) in the absence of scientific evidence. The aim of this study was to reveal the therapeutical effects and potential mechanisms of H. plantaginea flowers extract (HP) and its different polarity fractions (HPA∼D) on autoimmune CP (ACP) model rats. Sprague-Dawley male rats were randomly assigned to 13 groups (n=6/group). Except the sham group, all rats were injected with a mixture of prostate antigen and complete Freund's adjuvant on days 0, 7, and 21 to establish ACP model rats. Afterwards, ACP model rats were orally gavaged with HP or HPA∼D (1 and 4g/kg of raw herbal material) or positive drug (Prostat, 200mg/kg) daily from day 21 to day 50 for 30 days, while the sham and model groups were treated simultaneously with isopyknic of 0.3% sodium carboxymethyl cellulose. Histopathological analysis, biochemical parameters, and protein expression of prostate tissues were investigated. In comparison with the model group, all fraction groups experienced improved CP effects, including restored body weight, reduced prostate gland edema and prostate index, decreased prostatic leukocytes, increased prostatic lecithin bodies, and alleviated histopathological damage to prostate tissue. Furthermore, all fraction groups markedly inhibited the phosphorylated protein of nuclear factor kappa-B p65 (NF-κB p65), NF-κB inhibitor alpha (IκBα), c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (Erk), just another kinase 1 (JAK1), signal transducer and activator of transcription 3 (STAT3), phosphoinositide 3-kinase (PI3K), and protein kinase B (Akt) than the model group. All fractions of HP exerted significant anti-CP effects by inhibiting NF-κB, MAPKs, JAK-STAT and PI3K-Akt pathways in ACP model rats. These findings provide scientific evidence that H. plantaginea flowers can be used as a pivotal Mongolian medicine in clinical applications for the treatment of CP.

The use of extracorporeal shock wave therapy along with other non-drug methods in the treatment of chronic prostatitis from the standpoint of modern evidence-based medicine

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is one of the most common urogenital pathologies in working men. This disease could significantly negatively affect to the quality of life. The standard drug 3-Astherapy has not a corrective effect in some cases, depending on the phenotype of the disease, other groups of drugs and physiothera-peutic methods of treatment can be used additionally. Currently, the search is underway for the most effective non-drug and drug-based methods of treatment of CP/CPPS. One of these is extracorporeal shock wave therapy (ESWT) and the drug “Longidaza®”. This review analyzes and summarizes the results of large clinical studies evaluating the effectiveness of the use of ESWT in/without combination with drugs, as well as “Longidaza®” in patients with CP/CPPS. The mechanism of action is analyzed in detail and the key effects of the action of ESWT are demonstrated, namely: decrease of pain and dysuria, anti-inflammatory and antibacterial effects, lysis of prostate calcinates and fibrosis.

Study on the Application Value of the Content of Prostatic Exosomal Protein in the Treatment of Chronic Prostatitis.

To evaluate the application value of urinary prostatic exosomal protein (PSEP) in the treatment of chronic prostatitis (CP). We evaluated 174 patients with chronic prostatitis (44 cases of NIH-II, 65 cases of NIH-IIIa, and 65 cases of NIH-IIIb) who had obvious symptoms of chronic prostatitis syndrome and met the diagnostic criteria of National Institutes of Health Prostatitis from May 2018 to February 2021. They were also evaluated according to the clinical treatment's effect after six weeks of treatment. Urine samples of CP patients were collected before treatment and after six weeks of treatment, and the level of PSEP in the urine samples of all patients, before and after treatment, was detected by the ELISA method to evaluate the application value of PSEP in the end of CP curative effect. After six weeks of treatment, the total CPSI score of CP patients decreased significantly, compared to patients before treatment. After six weeks of treatment, the PSEP content in the patients' urine was compared to before treatment. The PSEP levels of CP subgroups decreased significantly (p < 0.05): NIH-II group (1.55 ± 1.39 ng/mL vs. 3.09 ± 2.66 ng/mL); NIH-IIIa group (1.68 ± 1.06 ng/mL vs. 3.34 ± 2.69 ng/mL); and NIH-IIIb group (1.57 ± 1.17 ng/mL vs. 3.14 ± 2.81 ng/mL). The concentration of PSEP in the urine of CP patients has a good application value for evaluating clinical treatment's effect on chronic prostatitis, and its concentration level may affect the development and outcome of prostatitis.

Study of the anti-inflammatory properties of a thick extract of Tribulus terrestris L.

The most promising direction in the treatment of chronic prostatitis is the use of medicinal plants and preparations based on them, which contain natural compounds with a broad spectrum of pharmacological activity: anti-inflammatory, antimicrobial, repara

A New Approach for Medicamentous Treatment of Patients with Lower Urinary Tract Symptoms Caused by Benign Prostate Hyperplasia and Chronic Prostatitis. Is It Possible to Prevent the Prostate Cancer?

Today the lower urinary tract symptoms (LUTS) in men are the actual problem. LUTS is an extremely polyetiological problem, but benign prostate hyperplasia (BPH) is the most often reason for its development. The problem of chronic prostatitis (CP) in patient of the older age with BPH is of great importance. These patients have the most pronounced symptoms of the lower urinary tract dysfunction. The therapy of patients with BPH and CP must lead to reducing of LUTS and improvement of quality of life, as well as to complications prevention associated with prostate enlargement and intravesical obstruction, such as acute urinary retention, recurrent urinary tract infection. The modern researches have presented that the combinations of herbal preparation with tamsulosin were more effective than monotherapy with α-adrenoblockers. That is why phytotherapy is considered an alternative option in the treatment of CP as first-line therapy and for the BPH initial stages in the complex treatment with other drugs. In contrast to “traditional” measures with one component, today multicomponent herbal preparations are popular. A natural complex preparation which contains saw palmetto extract (S. Repens), 3.3’ diindolylmethane, pumpkin seed extract, resveratrol, lycopene for hormonal balance normalization for men with BPH was analyzed. The advantage of the natural complex hormonal balance normalization for men with BPH is that it can be prescribed for the first LUTS signs that can prevent the symptoms progression and development of complications. Urologist received the preparation for effective LUTS treatment in patients with BPH and CP, as well for removal of postoperative dysuria.

Effectiveness and safety of acupuncture and moxibustion for chronic prostatitis: A protocol for an overview of systematic reviews and meta-analysis.

Background:Chronic prostatitis (CP) refers to a disease characterized by local pain and discomfort, urination discomfort, and quality of life. Acupuncture (ACU) and moxibustion are widely used in the treatment of CP, and the curative effect is satisfactory. Several systematic reviews (SRs) and meta-analyzes have reported the effectiveness of ACU and moxibustion in treating patients with CP. However, the evidence is not systematically integrated. This overview aims to integrate and evaluate the reliability of these SRs and the evidence generated from the ACU and moxibustion for CP meta-analysis.Methods:We will make a comprehensive retrieval in seven databases as following: Embase, Cochrane Library, Pubmed, Chinese databases SinoMed (previously called the Chinese Biomedical Database), Chinese National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), and Wanfang Data (WF). The time is limited from the construction of the library to May 2021. We will use the Assessment of Multiple Systematic Reviews-2 (AMSTAR-2) tool to evaluate methodological quality. Preferred Reporting Items for Systematic Reviews and Meta-analysis Protocols (PRISMA-P) will be used in the report checklist to assess the quality of reports in the study. The GRADE will be used to evaluate the included SRs and meta-analysis. Our reviewers will conduct SRs, qualification evaluation, data extraction, methodological quality and evidence quality screening in pairs. The outcomes of interest include: NIH-Chronic Prostatitis Symptom Index (NIH-CPSI), effective rate, other CP symptom scales, EPS-WBC, and adverse events. Evidence will be combined based on patient subgroups and results where appropriate.Results:The results will be published in a peer-reviewed journal.Trial registration number:INPLASY202150018.Conclusion:This overview will provide comprehensive evidence of ACU and moxibustion for patients with CP.

Efficacy of focused shock-wave therapy in the treatment of chronic prostatitis / chronic pelvic pain syndrome in men

Introduction. Chronic prostatitis / Chronic pelvic pain syndrome (CP / CPPS) is an extremely common condition for which no effective treatment has been found yet. Focused shockwave therapy (fSWT) is a safe method of physical intervention that could potentially be effective in CP / CPPS treating.Objective. To evaluate the efficacy and quality of life of patients after treatment of CP / CPPS with fSWT.Materials and methods. A prospective cohort study included 48 patients diagnosed with CP / CPPS. The patients attended the clinic three times a week for 4 weeks (12 sessions). Each time, patients received fSWT therapy sessions by “Chronic pelvic pain” protocol. One month after the last therapy session, the men completed the validated NIH-CPSI, IPSS, and QoL questionnaires.Results. The mean age of the patients was 40 ± 9 years. After the course of therapy, the score of Domain I “Pain” from 10.0 ± 4.7 to 6.3 ± 1.9 (p &lt; 0.001). At the same time, no statistically significant decrease was obtained in Domain II 'Urination' scores ((5,88 ± 2,40 vs 5,42 ± 1,64; p = 0,11). By the end of therapy for Domains III and IV, the scores had changed from 4.42 ± 0.90 and 4.04 ± 1.27 to 4.48 ± 1.01 and 3.08 ± 1.22, respectively (p &lt; 0,001). It is noted that the mean IPSS questionnaire score showed no statistically significant change over the treatment period (17,2 ± 4,8 vs 17,8 ± 4,8; p = 0,074)). QoL changed from 4.48 ± 0.99 to 2.46 ± 1.03 (p &lt; 0.001).Conclusion. The study demonstrated the efficacy of fSWT as a standalone method in the treatment of CP / CPPS.

69 - The possibility of using extracorporeal shockwave therapy in the treatment of chronic prostatitis

69 - The possibility of using extracorporeal shockwave therapy in the treatment of chronic prostatitis

Network Pharmacology and Molecular Docking Verify the Mechanism of Qinshi Simiao San in Treating Chronic Prostatitis in the Rat Model.

Background Using network pharmacology and molecular docking, this study aimed to explore the active pharmaceutical ingredients (APIs) and molecular mechanism of Qinshi Simiao San (QSSMS) in the treatment of chronic prostatitis (CP) and verify our findings in the rat model. Methods The APIs of QSSMS and the common targets of QSSMS and CP were screened from the TCMSP database. The STRING database and Cytoscape software were used to construct the network graph. The enriched GO and KEGG pathways were displayed by David software and R software. Molecular docking was performed to visualize key components and target genes. In addition, the rats model of CP was established to verify the molecular mechanism of QSSMS. Results Network pharmacology showed that the APIs of QSSMS mainly included quercetin, kaempferol, formononetin, isorhamnetin, and calycosin. QSSMS alleviated CP mainly through the negative regulation of the apoptotic process, oxidation-reduction process, inflammatory response, and immune response. Molecular docking showed that the APIs could bind to the corresponding targets. QSSMS repaired the pathological damage of prostate tissue, upregulated the expression of oxidative stress scavenging enzymes CAT and SOD, and downregulated the peroxidative product MDA, inflammatory factors IL-1β, IL-6, TNF-α, COX-2, PGE2, and NGF, and immune factors IgG and SIgA. Conclusion The APIs in QSSMS may inhibit inflammation in the rat CP model by regulating immune and oxidative stress.

Treatment of Chronic Prostatitis with Phosphodiesterase Type 5 Inhibitors

Our major aim was to systematically study the effectiveness of phosphodiesterase type 5 inhibitors in treating chronic prostatitis stage III and performed meta-analysis to evaluate the changes occurred in posttreatment scores of National Institutes of Health chronic prostatitis symptom index, international index of erectile function and international prostate symptom score. This meta-analysis was conducted according to the preferred reporting items for systematic reviews and meta-analyses guidelines. Comprehensive research was performed by using online resources like PubMed and the Wiley online library database to gather the relevant literature produced from the y 2010 to 2022. Two authors were assigned to independently collect the relevant information including author name, region of study, study design, treatment, publication year, sample size, voiding parameters, study inclusion and exclusion criteria, urological conditions, drug type, international prostate symptom score, international index of erectile function score, etc. In final screening 17 relevant studies were found. Out of these 17, 5 contained surgical procedure while 4 were narrative analysis. One study was incomplete regarding information. Finally, 7 studies were included for analysis. Total of 584 patients were involved in the selected studies. Three out of seven are from Italy region while two are from Japan and one was from Korea and Egypt respectively. Most of these studies used tadalafil monotherapy while one placebo-controlled trial. A significant difference in pain score, international prostate symptom score domain and National Institutes of Health chronic prostatitis symptom index were observed after consuming 5 mg tadalafil monotherapy. Everyday consumption of oral phosphodiesterase type 5 gave positive outcomes in terms of voiding. A significant difference was observed after using tadalafil monotherapy in the majority of the studies. Hence, tadalafil alone can be used to treat the type III chronic prostatitis.

Effectiveness and safety of acupuncture combined with traditional Chinese medicine in the treatment of chronic prostatitis: A systematic review and meta-analysis.

Objective:Chronic prostatitis (CP) is a common disease in the outpatient department of males and urology. Clinical studies have found that acupuncture combined with traditional Chinese medicine (TCM) has achieved good results in treating CP, but its efficacy and safety are not completely clear. This study aimed to investigate the efficacy and safety of acupuncture combined with TCM in the treatment of CP.Methods:Randomized controlled trials of acupuncture combined with TCM in treating CP were screened by searching PubMed, Embase, Cochrane Library, CNKI, etc. The retrieval time was from the database establishment date to March 31, 2021. The Cochrane Collaborative Risk Bias Assessment tool was used to evaluate literature's methodological quality of the literature. The RevMan5.4 software was used for the meta-analysis of outcome indicators. The TSA v0.9 software was used for sequential trial analysis (TSA) of effectiveness.Results:In this study, 19 related randomized controlled trial studies were included, with a total of 1831 cases. The results of the meta-analysis showed that acupuncture combined with TCM could significantly improve the clinical efficacy of CP (OR = 3.76, 95%CI: 2.82 to 5.02, P < .00001), reduce the total score of The National Institutes of Health chronic prostatitis symptom index (MD = −4.00, 95%CI: −4.67 to 3.33, P < .00001), and improve patients’ urination symptoms (MD = −1.10, 95%CI: −1.23 to −0.97, P < .00001), alleviated the pain symptoms of patients (MD = −2.38, 95%CI: −2.41 to −2.35, P < .00001), improved the quality of life of patients (MD = −1.69, 95%CI: −1.97 to −1.41, P < .00001), decreased the scores of TCM symptoms of patients (MD = −2.39, 95%CI: −3.45 to −1.33, P < .00001), and did not increase the adverse reactions of patients (MD = 1.09, 95%CI: 0.57 to 2.06, P = .8). The results of publication bias showed that this study was not affected by publication bias, and the conclusion was reliable. TSA showed that acupuncture combined with TCM was effective in treating CP.Conclusion:Acupuncture combined with TCM is safe and effective for alleviating CP. It can be used as an effective treatment for chronic prostatitis in the clinic.Registration number: DOI 10.17605/OSF.IO/Z8FJM.

Acupuncture for chronic prostatitis: A randomized controlled trial: 针刺治疗慢性前列腺炎:随机对照研究

ObjectiveTo explore whether there is a specific clinical effect of acupuncture in the treatment of chronic prostatitis. MethodsA total of 52 patients with chronic prostatitis were randomly divided into an acupuncture group (24 cases) and a placebo acupuncture group (28 cases). During the treatment, 1 case was dropped out in the placebo acupuncture group and 51 patients accomplished the clinical trial finally in two groups. In the acupuncture group, Shènshū (肾俞BL23), Zhōngliáo (中髎BL33), Huìyáng (会阳BL35) and Sānyīnjiāo (三阴交SP6) were selected. In the placebo acupuncture group, the non-meridian points located lateral to BL23, BL33, BL35 and SP6 were selected, respectively. The duration of treatment was 8 weeks in each group. In the first 4 weeks of treatment, the treatment was given once every two days, three times weekly. In the last 4 weeks of treatment, the treatment was given once every three days, twice a week. Totally, 20 acupuncture treatments were required in the whole trial. Before treatment, in week 4 and 8 of treatment and in follow-up, National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score and the comprehensive effect were evaluated in the two groups successively. ResultsIn week 4 and 8 of treatment, NIH-CPSI score in the acupuncture group was lower than that before treatment, respectively (both P < 0.05). In week 8 of treatment, NIH-CPSI score in the placebo acupuncture group was lower than that before treatment (P < 0.05). NIH-CPSI score in the acupuncture group was lower than the placebo acupuncture group in week 8 of treatment (P < 0.05). In follow-up, NIH-CPSI score of the two groups all decreased as compared with the score before treatment (both P < 0.05), and the score in the acupuncture group was lower than the placebo acupuncture group (P < 0.05). In the comparison of comprehensive effect, the total effective rate was 91.7% in the acupuncture group and was 74.1% in the placebo acupuncture group. The therapeutic effect in the acupuncture group was better than that of the placebo acupuncture group (P < 0.05). ConclusionAcupuncture relieves pelvic pain and urination symptoms and has a certain of long-term effect in patients with chronic prostatitis.

Лечение хронического простатита: современное состояние проблемы

A review of the literature on the urgent problem of urology, which is therapy of chronic prostatitis (CP) is presented. Despite numerous studies dedicated to the prevention and treatment of CP, it has not yet been possible to reduce the CP incidence. Therapeutic approaches aimed at improving the quality of life are not always effective due to the lack of a clear understanding of the etiology and pathogenesis of the disease. Leading Russian urologists recommend introducing into the complex therapy of CP a domestic drug from the cytomedin, namely Vitaprost, which causes a significant decrease in the severity of trophic disorders, inflammatory and congestive processes, improves microcirculation in the prostate, stimulates cellular and humoral immunity, all of which increase the effectiveness of CP therapy.